Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

PF-06372865 In Subjects With Chronic Low Back Pain

4 listopada 2016 zaktualizowane przez: Pfizer

A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of Pf-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control

PF-06372865 In Subjects With Chronic Low Back Pain

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

302

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • Arizona
      • Mesa, Arizona, Stany Zjednoczone, 85202
        • Agave Clinical Research, LLC
      • Phoenix, Arizona, Stany Zjednoczone, 85023
        • Arizona Research Center, Inc.
    • California
      • Anaheim, California, Stany Zjednoczone, 92804
        • Global Research
      • Fresno, California, Stany Zjednoczone, 93710
        • Neuro-Pain Medical Center
      • North Hollywood, California, Stany Zjednoczone, 91606
        • Providence Clinical Research
      • Wildomar, California, Stany Zjednoczone, 92595
        • Elite Clinical Trials, Incorporate
    • Connecticut
      • Stamford, Connecticut, Stany Zjednoczone, 06905
        • Stamford Therapeutics Consortium
    • Florida
      • DeLand, Florida, Stany Zjednoczone, 32720
        • Avail Clinical Research, LLC
      • Fort Lauderdale, Florida, Stany Zjednoczone, 33306
        • S&W Clinical Research
      • Gainesville, Florida, Stany Zjednoczone, 32605
        • Florida Research Network, LLC
      • Hollywood, Florida, Stany Zjednoczone, 33024
        • Broward Research Group
      • Jacksonville, Florida, Stany Zjednoczone, 32216
        • Jacksonville Center for Clinical Research
      • Orlando, Florida, Stany Zjednoczone, 32806
        • Compass Research, LLC
      • Pembroke Pines, Florida, Stany Zjednoczone, 33028
        • Pines Clinical Research Inc.
      • Port Orange, Florida, Stany Zjednoczone, 32129
        • Accord Clinical Research, LLC
      • South Miami, Florida, Stany Zjednoczone, 33143
        • Miami Research Associates
      • South Miami, Florida, Stany Zjednoczone, 33143
        • Arthritis & Rheumatic Care Center
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30344
        • Better Health Clinical Research, Inc.
      • Blue Ridge, Georgia, Stany Zjednoczone, 30513
        • River Birch Research Alliance, LLC
      • Columbus, Georgia, Stany Zjednoczone, 31904
        • Columbus Regional Research Institute
      • Columbus, Georgia, Stany Zjednoczone, 31901
        • Family medicine center
      • Marietta, Georgia, Stany Zjednoczone, 30060
        • Drug Studies America
      • Newnan, Georgia, Stany Zjednoczone, 30265
        • Better Health Clinical Research, Inc.
      • Newnan, Georgia, Stany Zjednoczone, 30265
        • Better Health Clinical Research, Inc./Georgia Pain & Spine Care, Inc.
      • Savannah, Georgia, Stany Zjednoczone, 31405
        • Southeast Regional Research Group
      • Woodstock, Georgia, Stany Zjednoczone, 30189
        • North Georgia Clinical Research
      • Woodstock, Georgia, Stany Zjednoczone, 30189
        • North Georgia Internal Medicine
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60657
        • Chicago Anesthesia Associates
    • Louisiana
      • Lake Charles, Louisiana, Stany Zjednoczone, 70601
        • Centex Studies, Inc
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02131
        • Boston Clinical Trials
      • Methuen, Massachusetts, Stany Zjednoczone, 01844
        • ActivMed Practices & Research, Inc.
    • Mississippi
      • Jackson, Mississippi, Stany Zjednoczone, 39202
        • CRC of Jackson
      • Jackson, Mississippi, Stany Zjednoczone, 39202
        • Physician's Surgery Center
    • New York
      • Hartsdale, New York, Stany Zjednoczone, 10530
        • Drug Trials America
      • Rochester, New York, Stany Zjednoczone, 14618
        • AAIR Research Center
    • North Carolina
      • Raleigh, North Carolina, Stany Zjednoczone, 27612
        • Wake Research Associates, LLC
      • Raleigh, North Carolina, Stany Zjednoczone, 27612
        • Wake Internal Medicine Consultants, Inc.
      • Winston-Salem, North Carolina, Stany Zjednoczone, 27103
        • The Center for Clinical Research
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97210
        • Summit Research Network (Oregon), Inc.
    • Pennsylvania
      • Duncansville, Pennsylvania, Stany Zjednoczone, 16635
        • Altoona Center for Clinical Research
    • Rhode Island
      • Warwick, Rhode Island, Stany Zjednoczone, 02886
        • Omega Medical Research
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77074
        • Clinical Trial Network
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Progressive Clinical Research
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Lee Medical Associates, PA
    • Virginia
      • Norfolk, Virginia, Stany Zjednoczone, 23502
        • National Clinical Research - Norfolk, Inc.
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Summit Research Network (Seattle) Llc

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

-

Exclusion Criteria:

-

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: PF-06372865
Daily BID dosing for 4 weeks
Lek: PF-06372865
Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
Komparator placebo: Placebo
Daily BID dosing for 4 weeks
Lek: Placebo
Placebo for PF-06372865 and placebo for naproxen daily
Aktywny komparator: Naproxen
Daily BID dosing for 4 weeks
Lek: Naproxen
500 mg BID for 4 weeks

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Daily Low Back Pain Intensity (LBPI) Score as Measured by an 11-point Numeric Rating Scale (NRS) at Week 4
Ramy czasowe: Baseline, Week 4
Daily average low back pain was assessed on an 11-point numeric rating scale (NRS). Participants described their average low back pain during the past 24 hours on a scale ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate higher pain. Baseline value was calculated as the mean of the scores over the last 7 days in the placebo run-in period, prior to randomization. Post-baseline weekly scores were calculated based on the mean of the scores over the 7 days prior to and including the day at the end of the corresponding week.
Baseline, Week 4
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Ramy czasowe: Baseline up to 28 days after the last dose of study treatment (Day 56)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. The SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious adverse events.
Baseline up to 28 days after the last dose of study treatment (Day 56)
Number of Participants With Laboratory Abnormalities
Ramy czasowe: Baseline up to 28 days after the last dose of study treatment (Day 56)
Abnormality criteria included: hemoglobin, hematocrit and red blood cells (RBCs) (less than [<] 0.8*lower limit of normal [LLN]); white blood cells (WBC) (<0.6*LLN, greater than [>] 1.5*upper limit of normal [ULN]); MCV, MCH, MCHC (<0.9*LLN, >1.1*ULN); platelets (<0.5*LLN>, >1.75*ULN); neutrophils, lymphocytes(<0.8*LLN, >1.2*ULN); eosinophils, basophils, monocytes (>1.2*ULN); total bilirubin (>1.5*ULN); aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase (>3*ULN); total protein, albumin (<0.8*LLN, >1.2*ULN); creatinine, blood urea nitrogen (>1.3*ULN); glucose (<0.6*LLN, >1.5*ULN); uric acid (>1.2*ULN); sodium, potassium, chloride, calcium, bicarbonate (<0.9*LLN, >1.1*ULN); urine pH (<4.5, >8); qualitative urine glucose, ketones, protein, blood values (greater than or equal to [>=] 1) in urine dipstick test; urine RBC, WBC (>=20); hyaline casts (>1), bacteria (>20).
Baseline up to 28 days after the last dose of study treatment (Day 56)
Number of Participants With Vital Sign Abnormalities
Ramy czasowe: Baseline up to Follow-up (44 days)
Participants who met the criteria for abnormal findings in vital signs data were reported. Criteria for abnormalities in vital signs: supine systolic blood pressure (SBP) <90 millimeter of mercury (mmHg), supine diastolic BP (DBP) <50 mmHg, supine pulse rate <40 beats per minute (bpm) or >120 bpm. Maximum increase or decrease from baseline in supine SBP >=30 mmHg and maximum increase or decrease from baseline in supine DBP >=20 mmHg.
Baseline up to Follow-up (44 days)
Number of Participants With Electrocardiogram (ECG) Abnormalities
Ramy czasowe: Baseline up to Follow-up (44 days)
Participants with abnormal ECG findings were reported. Criteria for potential clinical concern in ECG parameters: maximum (max.) PR interval of >=300 milliseconds (msec), maximum QRS interval >=140 msec, maximum QTCF interval (Fridericia's Correction) of 450 to <480 msec, 480 to <500 msec and >=500 msec, maximum of >=25 percent (%) increase from baseline (IFB) value of >200 msec and >=50% for baseline value of less than or equal to (<=) 200 msec for PR interval, maximum increase from baseline of >=50% for QRS interval, maximum increase from baseline of >=30 msec to <60 msec and maximum increase from baseline of >60 msec in QTCF interval (Fridericia's Correction).
Baseline up to Follow-up (44 days)
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS)
Ramy czasowe: Screening, Baseline, Week 1, 2, 3, 4
The C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment [C-CASA]) is an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS assessed whether participant experienced following: completed suicide =1, suicide attempt =2 (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior =3 ("Yes" on "preparatory acts or behavior"), suicidal ideation =4 ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior =7 ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").
Screening, Baseline, Week 1, 2, 3, 4
Change From End of Treatment Visit in Physician's Withdrawal Checklist (PWC) Score at Follow-up Visit
Ramy czasowe: End of treatment (Day 30), follow-up (Day 44)
PWC is a 20 item physician rated interview to measure anxiolytic drug withdrawal-related signs and symptoms. Each individual item score ranges from 0 (not present) to 3 (severe), where higher scores = more affected condition. PWC total score range from 0 (not present) to 60 (severe), where higher score = more affected condition. Change: score at follow-up visit minus score at the end of treatment visit.
End of treatment (Day 30), follow-up (Day 44)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change From Baseline in Daily Low Back Pain Intensity (LBPI) as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1, 2 3 and 4
Ramy czasowe: Baseline, Week 1, 2, 3, 4
Average back pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Participants described their average low back pain during the past 24 hours by choosing the appropriate number from 0 to 10.
Baseline, Week 1, 2, 3, 4
Percent Change From Baseline in Daily Low Back Pain Intensity (LBPI) as Measured by an 11-point Numeric Rating Scale (NRS) at Week 1, 2, 3 and 4
Ramy czasowe: Baseline, Week 1, 2, 3, 4
Average back pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Participants described their average low back pain during the past 24 hours by choosing the appropriate number from 0 to 10.
Baseline, Week 1, 2, 3, 4
Number of Participants With Sustained Response Rates in Daily Average LBPI NRS Scores at Greater Than or Equal to (>=) 30 Percent and >=50 Percent Reduction From Baseline
Ramy czasowe: Baseline up to Week 4
Average back pain was assessed with an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Participants described their average low back pain during the past 24 hours by choosing the appropriate number from 0 to 10. Percentage of reduction from baseline in the daily average LBPI NRS score was calculated as: ([daily value - baseline value] divided by baseline value) multiplied by 100. Number of participants with sustained response rates (for a minimum of 4 consecutive days) in the daily average LBPI NRS scores that were at >=30 percent and >=50 percent reduced from baseline were reported.
Baseline up to Week 4
Number of Participants Withdrawn Due to Lack of Efficacy
Ramy czasowe: Baseline up to Week 4
Participants withdrew from the study due to lack of efficacy (insufficient clinical response) were reported.
Baseline up to Week 4
Time to Withdrawal Due to Lack of Efficacy
Ramy czasowe: Baseline up to Week 4
Kaplan Meier and Cox Proportional Hazards analyses were to be used to compute the time to withdrawal due to lack of efficacy. Withdrawal due to lack of efficacy was identified from the participant summary case report form (CRF) page and where reason was identified as "Insufficient Clinical Response". Time to withdrawal was calculated as Date of withdrawal - Date of Randomization.
Baseline up to Week 4
Number of Participants Using Rescue Medication
Ramy czasowe: Week 1, 2, 3, 4
Participants were permitted to use any commercial product (tablet/caplet/capsule) of acetaminophen (paracetamol) 500 mg as a rescue medication. Number of participants who used rescue medication were reported.
Week 1, 2, 3, 4
Number of Days Participants Used the Rescue Medication
Ramy czasowe: Week 1, 2, 3, 4
The number of days for which the participants used the rescue medication were reported. Participants recorded the usage of acetaminophen rescue medication in the daily diary.
Week 1, 2, 3, 4
Amount of Rescue Medication Used by the Participants
Ramy czasowe: Week 1, 2, 3, 4
The amount of rescue medication (Acetaminophen [paracetamol]) used was reported. Participants were permitted to use any commercial product of acetaminophen tablet/caplet/capsule.
Week 1, 2, 3, 4
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 1, 2, and 3
Ramy czasowe: Baseline, Week 1, 2, 3
Each participant assessed his or her own disability due to low back pain using the RMDQ worksheet. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total possible scores ranges from 0 to 24, with higher scores indicating greater disability.
Baseline, Week 1, 2, 3
Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) Total Score at Week 4
Ramy czasowe: Baseline, Week 4
Each participant assessed his or her own disability due to low back pain using the RMDQ worksheet. The RMDQ total score was calculated as the total number of statements that were checked; the RMDQ total possible scores ranges from 0 to 24, with higher scores indicating greater disability.
Baseline, Week 4
Change From Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) at Week 2 and 4
Ramy czasowe: Baseline, Week 2, Week 4
This test assesses verbal learning and memory. Participants are given a list of 12 words and asked to repeat as many words as they can recall during 3 separate learning trials. The total recall score ranges from 0 (no memory) to 36 (best memory) while the delayed recall trial score ranges from 0 (no memory) to 12 (best memory); higher scores indicated greater verbal learning and recall.
Baseline, Week 2, Week 4
Chronic Low Back Pain (CLBP) Responder Index Analysis
Ramy czasowe: Week 1, 2, 3, 4
Participants were successful responders if they had any of the following: >=30 percent reduction in mean daily average LBPI from baseline to particular week; decrease of >=30 percent in participant's global assessment of low back pain (disease activity) from baseline to particular week or no worsening (increase) in RMDQ total score from baseline to particular week.
Week 1, 2, 3, 4
Change From Baseline in Participant's Global Assessment (PtGA) of Low Back Pain Score at Week 1, 2, 3 and 4
Ramy czasowe: Baseline, Week 1, 2, 3, 4
Participant rated 5-point Likert scale ranging from 0 (no pain) to 4 (worst possible pain) with a higher score indicating greater level of pain.
Baseline, Week 1, 2, 3, 4
Patient Global Impression of Change (PGI-C) Score
Ramy czasowe: Week 1, 2, 3, 4
PGI-C was a participant rated instrument to measure participant's assessment of change in his or her overall status since the previous visit on a 7-point scale; ranging from 1 (very much improved) to 7 (very much worse), where higher scores indicated more worsening.
Week 1, 2, 3, 4
Number of Participants With Global Evaluation of Study Medication (GESM) at Week 4
Ramy czasowe: Week 4
Participants rated their study treatment by GESM questionnaire. It was a qualitative measure of efficacy utilizing a 4-point Likert scale ranging from 1 (poor) to 4 (excellent), where higher score indicated a better overall response to the treatment. Number of participants who reported a particular score had been reported.
Week 4
Plasma Concentration of PF-06372865
Ramy czasowe: Baseline, Week 1, 2, 3, 4
Data was calculated by setting concentration values below the lower limit of quantification (LLOQ) to zero. The LLOQ was <0.0100 nanogram per milliliter (ng/mL).
Baseline, Week 1, 2, 3, 4
Plasma Concentration of Naproxen
Ramy czasowe: Baseline, Week 1, 2, 3, 4
Data was calculated by setting concentration values below the LLOQ to zero. The LLOQ was <1000 ng/mL.
Baseline, Week 1, 2, 3, 4

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 października 2014

Zakończenie podstawowe (Rzeczywisty)

1 sierpnia 2015

Ukończenie studiów (Rzeczywisty)

1 sierpnia 2015

Daty rejestracji na studia

Pierwszy przesłany

9 października 2014

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 października 2014

Pierwszy wysłany (Oszacować)

13 października 2014

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

4 stycznia 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

4 listopada 2016

Ostatnia weryfikacja

1 listopada 2016

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • B7431006

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na PF-06372865

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Kenya

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj